Changes in 25-hydroxyvitamin D3 level and its significance in children with Kawasaki disease

ZHANG Yuan-Da; LI Rong-Min; JI Chao-Yu; ZHANG Xiao-Long; ZHANG Yu; DONG Qing-Wei; MA Lei

doi:10.7499/j.issn.1008-8830.2016.03.004

PDF(1083 KB)

Chinese Journal of Contemporary Pediatrics ›› 2016, Vol. 18 ›› Issue (3) : 211-214. DOI: 10.7499/j.issn.1008-8830.2016.03.004

CLINICAL RESEARCH

Changes in 25-hydroxyvitamin D₃ level and its significance in children with Kawasaki disease

ZHANG Yuan-Da, LI Rong-Min, JI Chao-Yu, ZHANG Xiao-Long, ZHANG Yu, DONG Qing-Wei, MA Lei

Author information +

History +

Abstract

Objective To investigate the changes in the serum level of 25-hydroxyvitamin D₃ [25-(OH)D₃] and its significance in children with Kawasaki disease (KD). Methods The clinical data of 242 KD children were collected. According to the presence or absence of coronary artery lesion (CAL), these children were classified into CAL group (63 children) and non-CAL (NCAL) group (179 children). According to the efficacy of intravenous immunoglobulin (IVIG), these children were classified into IVIG-sensitive group (219 children) and no-IVIG-response group (23 children). A total of 40 healthy children (control group) and 40 children with acute upper respiratory tract infection (AURI group) were enrolled as controls. Enzyme-linked immunosorbent assay was applied to measure the serum level of 25-(OH)D₃. Results Before IVIG treatment, the AURI, NCAL, and CAL groups had significantly lower serum levels of 25-(OH)D₃ than the control group (P<0.05); the CAL group had a significantly lower serum level of 25-(OH)D₃ than the AURI and NCAL groups (P<0.05); the AURI, IVIG-sensitive, and no-IVIG-response groups had significantly lower serum levels of 25-(OH)D₃ than the control group (P<0.05); the no-IVIG-response group had a significantly lower serum level of 25-(OH)D₃ than the AURI and IVIG-sensitive groups (P<0.05). After IVIG treatment, the CAL group had a significantly lower serum level of 25-(OH)D₃ than the NCAL and control groups (P<0.05); the no-IVIG-response group had a significantly lower serum level of 25-(OH)D₃ than the IVIG-sensitive and control groups (P<0.05). Conclusions KD children may experience a reduction in the serum level of 25-(OH)D₃. With a greater reduction in the serum level of 25-(OH)D₃, the possibility of CAL and KD with no response to treatment increases.

Key words

Kawasaki disease / 25-hydroxyvitamin D₃ / Coronary artery lesion / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

ZHANG Yuan-Da, LI Rong-Min, JI Chao-Yu, ZHANG Xiao-Long, ZHANG Yu, DONG Qing-Wei, MA Lei. Changes in 25-hydroxyvitamin D₃ level and its significance in children with Kawasaki disease[J]. Chinese Journal of Contemporary Pediatrics. 2016, 18(3): 211-214 https://doi.org/10.7499/j.issn.1008-8830.2016.03.004

References

[1] Matsunaga A, Harita Y, Shibagaki Y, et al. Identification of 4-trimethylaminobutyraldehyde dehydrogenase (TMABADH) as a candidate serum autoantibody target for Kawasaki Disease[J]. PLoS One, 2015, 10(5): e0128189.
[2] Alhammadi AH, Hendaus MA. Comorbidity of Kawasaki disease and group A streptococcal pleural effusion in a healthy child: a case report[J]. Int J Gen Med, 2013, 6: 613-616.
[3] Bal AK, Prasad D, Pamintuan MAU, et al. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease[J]. Pediatr Neonatol, 2014, 55(5): 387-392.
[4] Jeffery LE, Qureshi OS, Gardner D, et al.Vitamin D antagonises the suppressive effect of inflammatory cytokines on CTLA-4 expression and regulatory function[J]. PLoS One, 2015, 10(7): e0131539.
[5] Mozos I, Marginean O. Links between Vitamin D deficiency and cardiovascular diseases[J]. Biomed Res Int, 2015, 2015: 109275.
[6] Stagi S, Rigante D, Lepri G, et al. Severe vitamin D deficiency in patients with Kawasaki disease: a potential role in the risk to develop heart vascular abnormalities[J]. Clin Rheumatol, 2015: 1-8.
[7] Newburger JW, Takahashi M, Gerber MH, et al. Diagnosis, treatment, and long-term management of Kawasaki disease:a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association[J]. Pediatrics, 2004, 114(6): 1708-1733.
[8] 《中华儿科杂志》编辑委员会, 中华医学会儿科学分会心血管学组, 中华医学会儿科学分会免疫学组. 川崎病专题讨论会纪要[J]. 中华儿科杂志, 2007, 45(11): 826-830．
[9] 王新凤, 邓秀玲, 汪南平. 维生素D 在心血管疾病中的作用[J]. 生理科学进展, 2013, 44(3): 223-226.
[10] Vojinovic J, Cimaz R.Vitamin D-update for the pediatric rheumatologists[J]. Pediatr Rheumatol Online J, 2015, 13: 18.
[11] Nakamura Y. Epidemiology of Kawasaki disease[J].Nihon Rinsho, 2014, 72(9): 1536-1541.
[12] Liefaard MC, Ligthart S, Vitezova A, et al.Vitamin D and c-reactive protein: a mendelian randomization study[J]. PLoS One, 2015, 10(7): e0131740.
[13] Sommer A, Fabri M.Vitamin D regulates cytokine patterns secreted by dendritic cells to promote differentiation of IL-22-producing T Cells[J]. PLoS One, 2015, 10(6): e0130395.
[14] Hashemi SM, Mokhtari SM, Sadeqhi M, et al. Effect of vitamin D therapy on endothelial function in ischemic heart disease female patients with vitamin D deficiency or insufficiency: a primary report[J]. ARYA Atheroscler, 2015, 11(1): 54-59.
[15] 高卫卫, 李培, 施毅. 维生素D 对免疫系统的调节作用[J]. 中华哮喘杂志(电子版), 2013, 7(4): 43-46.
[16] Alyami A, Soares MJ, Sherriff JL, et al. A systematic review protocol examining the effect of vitamin D supplementation on endothelial function[J]. BMJ Open, 2015, 5(6): e006835.
[17] Kudo K, Hasegawa S, Suzuki Y, et al. 1α,25-Dihydroxyvitamin D(3) inhibits vascular cellular adhesion molecule-1 expression and interleukin-8 production in human coronary arterial endothelial cells[J]. J Steroid Biochem Mol Biol, 2012, 132(s 3-5): 290-294.